- Home
- BMGL vs ALXO Comparison
BMGL vs ALXO Comparison
Compare BMGL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- ALXO
- Stock Information
- Founded
- BMGL 2001
- ALXO 2015
- Country
- BMGL Singapore
- ALXO United States
- Employees
- BMGL N/A
- ALXO N/A
- Industry
- BMGL
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- BMGL
- ALXO Health Care
- Exchange
- BMGL NYSE
- ALXO Nasdaq
- Market Cap
- BMGL 75.9M
- ALXO 76.5M
- IPO Year
- BMGL 2025
- ALXO 2020
- Fundamental
- Price
- BMGL $4.45
- ALXO $0.55
- Analyst Decision
- BMGL
- ALXO Strong Buy
- Analyst Count
- BMGL 0
- ALXO 6
- Target Price
- BMGL N/A
- ALXO $4.14
- AVG Volume (30 Days)
- BMGL 141.3K
- ALXO 529.8K
- Earning Date
- BMGL 01-01-0001
- ALXO 05-08-2025
- Dividend Yield
- BMGL N/A
- ALXO N/A
- EPS Growth
- BMGL 16.23
- ALXO N/A
- EPS
- BMGL 0.09
- ALXO N/A
- Revenue
- BMGL $7,428,776.00
- ALXO N/A
- Revenue This Year
- BMGL N/A
- ALXO N/A
- Revenue Next Year
- BMGL N/A
- ALXO N/A
- P/E Ratio
- BMGL $47.29
- ALXO N/A
- Revenue Growth
- BMGL 3.32
- ALXO N/A
- 52 Week Low
- BMGL $3.63
- ALXO $0.46
- 52 Week High
- BMGL $5.50
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- ALXO 37.26
- Support Level
- BMGL N/A
- ALXO $0.46
- Resistance Level
- BMGL N/A
- ALXO $0.63
- Average True Range (ATR)
- BMGL 0.00
- ALXO 0.06
- MACD
- BMGL 0.00
- ALXO 0.02
- Stochastic Oscillator
- BMGL 0.00
- ALXO 42.86
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.